Research output per year
Research output per year
Personal profile
Public Profile
Dr. Thompson-Peach is a research fellow in the Myeloid Metabolism Laboratory at the South Australian Health and Medical Research Institute. Her research focuses on designing and developing novel mutation-specific therapies for blood cancers with recurrent mutations. She is particularly focused on myeloproliferative neoplasms, specifically CALR-driven myelofibrosis. Dr. Thompson-Peach is passionate about developing mutation-specific therapies for a cohort of patients who currently lack effective treatment options.
Education/Academic qualification
PhD, Analysis of hereditary and putative breast cancer susceptibility genes in BRCA1 and BRCA2 mutation-negative individuals
10 Mar 2014 → 19 Oct 2019
Award Date: 26 Mar 2020
Bachelor of Science (Honours), Monoallelic expression of BRCA1 and BRCA2 in mutation-negative patients with a familial history of breast and ovarian cancer
10 Feb 2013 → 22 Nov 2013
Award Date: 10 Apr 2014
Diploma, Diploma of Language, Flinders University
1 Mar 2009 → 20 Nov 2012
Award Date: 8 Mar 2013
Bachelor's Degree, Bachelor of Medical Science, Flinders University
1 Feb 2008 → 20 Nov 2012
Award Date: 8 Mar 2013
External positions
Casual Academic, Flinders University
1 Mar 2015 → …
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
Hong, L. E., Wechalekar, M. D., Kutyna, M., Small, A., Lim, K., Thompson-Peach, C., Li, J. J., Chhetri, R., Scott, H. S., Brown, A., Hahn, C. N., Yeung, D. T., Sajid, S., Robinson, N., Thomas, R., Branford, S., D'Andrea, R. J., Samaraweera, S. E., Patnaik, M. & Proudman, S. & 4 others, , 2024, (Accepted/In press) In: Blood.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability
Thomas, D., Wu, M., Nakauchi, Y., Zheng, M., Thompson-Peach, C. A. L., Lim, K., Landberg, N., Köhnke, T., Robinson, N., Kaur, S., Kutyna, M., Stafford, M., Hiwase, D., Reinisch, A., Peltz, G. & Majeti, R., 2023, In: Cancer Discovery. 13, 2, p. 496-515 20 p.Research output: Contribution to journal › Article › peer-review
Open Access19 Citations (Scopus) -
Thrombopoietin-independent Megakaryocyte Differentiation of Hematopoietic Progenitor Cells from Patients with Myeloproliferative Neoplasms
Thompson-Peach, C. A. L., Foßelteder, J., Reinisch, A. & Thomas, D., 20 Jan 2023, In: Bio-protocol. 13, 2, e4592.Research output: Contribution to journal › Article › peer-review
Open Access -
A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure
Kutyna, M. M., Kok, C. H., Lim, Y., Tran, E. N. H., Campbell, D., Paton, S., Thompson-Peach, C., Lim, K., Cakouros, D., Arthur, A., Hughes, T., Kumar, S., Thomas, D., Gronthos, S. & Hiwase, D. K., Nov 2022, In: Leukemia. 36, 11, p. 2678-2689 12 p.Research output: Contribution to journal › Article › peer-review
Open Access12 Citations (Scopus) -
Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia (Nature Communications, (2022), 13, 1, (2614), 10.1038/s41467-022-30223-9)
Bassal, M. A., Samaraweera, S. E., Lim, K., Benard, B. A., Bailey, S., Kaur, S., Leo, P., Toubia, J., Thompson-Peach, C., Nguyen, T., Maung, K. Z. Y., Casolari, D. A., Iarossi, D. G., Pagani, I. S., Powell, J., Pitson, S., Natera, S., Roessner, U., Lewis, I. D. & Brown, A. L. & 7 others, , Dec 2022, In: Nature Communications. 13, 1, 4131.Research output: Contribution to journal › Comment/debate › peer-review
Open Access1 Citation (Scopus)